TENX Tenax Therapeutics, Inc.

2.30
-0.2  -8%
Previous Close 2.50
Open 2.51
Price To book 1.51
Market Cap 64.67M
Shares 28,119,000
Volume 719,389
Short Ratio 4.50
Av. Daily Volume 277,665

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data due January 2017.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. Tenax Therapeutics, Inc. Review of Clinical Trials and Financials
  2. Is KemPharm Inc (KMPH) A Good Stock To Buy?
  3. TENX: LEVO-CTS Enrolment Complete; Anticipate January Topline Readout
  4. Tenax Therapeutics Announces Completion of Enrollment for Phase 3 LEVO-CTS Trial in Cardiac Surgery
  5. Q3 2016 Tenax Therapeutics Inc Earnings Release - Time Not Supplied
  6. Tenax Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
  7. Tenax Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
  8. Investor Calendar Invites You to the Tenax Therapeutics Third Quarter 2016 Business Review and Update on Thursday, November 10, 2016
  9. TENAX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  10. Tenax Therapeutics to Discuss Third Quarter 2016 Financial Results and Provide Business Update
  11. Tenax Therapeutics to Discuss Third Quarter 2016 Financial Results and Provide Business Update
  12. TENX: LeoPARDS Trial Fails Endpoints; Year End 2016 Readout for LEVO-CTS.
  13. Here’s What Happened With Alnylam Pharmaceuticals, Inc. (ALNY) and Tenax Therapeutics Inc (TENX)
  14. Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan
  15. Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan
  16. TENX: Higher Costs in FY:16; Dual Readouts in 4Q:16 Maintaining $10 Target
  17. Tenax Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update
  18. Tenax Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update
  19. TENAX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  20. Tenax Therapeutics to Discuss Second Quarter 2016 Financial Results and Provide Business Update